Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Antimicrobial Resistance & Infection Control
Published in: Antimicrobial Resistance & Infection Control 1/2020

01-12-2020 | Antibiotic | Review

The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase–negative staphylococci strains: a systematic review and meta-analysis

Authors: Aref Shariati, Masoud Dadashi, Zahra Chegini, Alex van Belkum, Mehdi Mirzaii, Seyed Sajjad Khoramrooz, Davood Darban-Sarokhalil

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2020

Login to get access

Abstract

Objective

Methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase-negative Staphylococcus (MRCoNS) are among the main causes of nosocomial infections, which have caused major problems in recent years due to continuously increasing spread of various antibiotic resistance features. Apparently, vancomycin is still an effective antibiotic for treatment of infections caused by these bacteria but in recent years, additional resistance phenotypes have led to the accelerated introduction of newer agents such as linezolid, tigecycline, daptomycin, and quinupristin/dalfopristin (Q/D). Due to limited data availability on the global rate of resistance to these antibiotics, in the present study, the resistance rates of S. aureus, Methicillin-resistant S. aureus (MRSA), and CoNS to these antibiotics were collected.

Method

Several databases including web of science, EMBASE, and Medline (via PubMed), were searched (September 2018) to identify those studies that address MRSA, and CONS resistance to linezolid, tigecycline, daptomycin, and Q/D around the world.

Result

Most studies that reported resistant staphylococci were from the United States, Canada, and the European continent, while African and Asian countries reported the least resistance to these antibiotics. Our results showed that linezolid had the best inhibitory effect on S. aureus. Although resistances to this antibiotic have been reported from different countries, however, due to the high volume of the samples and the low number of resistance, in terms of statistical analyzes, the resistance to this antibiotic is zero. Moreover, linezolid, daptomycin and tigecycline effectively (99.9%) inhibit MRSA. Studies have shown that CoNS with 0.3% show the lowest resistance to linezolid and daptomycin, while analyzes introduced tigecycline with 1.6% resistance as the least effective antibiotic for these bacteria. Finally, MRSA and CoNS had a greater resistance to Q/D with 0.7 and 0.6%, respectively and due to its significant side effects and drug-drug interactions; it appears that its use is subject to limitations.

Conclusion

The present study shows that resistance to new agents is low in staphylococci and these antibiotics can still be used for treatment of staphylococcal infections in the world.
Literature
1.
Braun T, Kahanov L, Dannelly K, Lauber C. CA-MRSA infection incidence and Care in High School and Intercollegiate Athletics. Med Sci Sports Exerc. 2016;48:1530–8.PubMedCrossRef
2.
Fooladvand S, Sarmadian H, Habibi D, van Belkum A, Ghaznavi-Rad E. High prevalence of methicillin resistant and enterotoxin gene-positive Staphylococcus aureus among nasally colonized food handlers in Central Iran. Eur J Clin Microbiol Infect Dis. 2019;38:87–92.PubMedCrossRef
3.
Yousefi M, Pourmand MR, Fallah F, Hashemi A, Mashhadi R, Nazari-Alam A. Characterization of Staphylococcus aureus biofilm formation in urinary tract infection. Iran J Public Health. 2016;45:485–93.PubMedPubMedCentral
4.
Lee L-H, Zainal N, Azman A-S, Eng S-K, Goh B-H, Yin W-F, Ab Mutalib N-S, Chan K-G. Diversity and antimicrobial activities of actinobacteria isolated from tropical mangrove sediments in Malaysia. Sci World J. 2014;2014.
5.
Ghahremani M, Jazani NH, Sharifi Y. Emergence of vancomycin-intermediate and-resistant Staphylococcus aureus among methicillin-resistant S aureus isolated from clinical specimens in the northwest of Iran. J Global Antimicrob Resist. 2018;14:4–9.CrossRef
6.
Abbasian S, Farahani NN, Mir Z, Alinejad F, Haeili M, Dahmardehei M, Mirzaii M, Khoramrooz SS, Nasiri MJ, Darban-Sarokhalil D. Genotypic characterization of Staphylococcus aureus isolated from a burn Centre by using agr, spa and SCCmec typing methods. New Microbes New Infect. 2018;26:15–9.PubMedPubMedCentralCrossRef
7.
Bijari A, Zade MH, Hatami S, Kalantar E, Sepehr MN, Kabir K, Zahmatkesh E, Naseri MH, Sarokhalil DD. High frequency of methicillin-resistant staphylococcus aureus in intensive care unit in Karaj, Iran. Arch Clin Infect Dis. 2018;13.
8.
Kemung HM, Tan LT-H, Khan TM, Chan K-G, Pusparajah P, Goh B-H, Lee L-H. Streptomyces as a prominent resource of future anti-MRSA drugs. Front Microbiol. 2018;9.
9.
Sader HS, Farrell DJ, Flamm RK, Jones RN. Daptomycin activity tested against 164 457 bacterial isolates from hospitalised patients: summary of 8 years of a worldwide surveillance Programme (2005–2012). Int J Antimicrob Agents. 2014;43:465–9.PubMedCrossRef
10.
Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis. 2012;206:1160–7.PubMedPubMedCentralCrossRef
11.
Bæk KT, Thøgersen L, Mogenssen RG, Mellergaard M, Thomsen LE, Petersen A, Skov S, Cameron DR, Peleg AY, Frees D. Step-wise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene. Antimicrob Agents Chemother. 2015;(AAC):01303–15.
12.
Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis. 2005;41:S303–14.PubMedCrossRef
13.
Peterson LR. A review of tigecycline—the first glycylcycline. Int J Antimicrob Agents. 2008;32:S215–22.PubMedCrossRef
14.
Quiles-Melero I, Gómez-Gil R, Romero-Gómez MP, Sánchez-Díaz AM, de Pablos M, García-Rodriguez J, Gutiérrez A, Mingorance J. Mechanisms of linezolid resistance among staphylococci in a tertiary hospital. J Clin Microbiol. 2013;51:998–1001.PubMedPubMedCentralCrossRef
15.
Welte T, Pletz MW. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents. 2010;36:391–400.PubMedCrossRef
16.
Abdel-Hamid ME, Phillips OA. LC-MS/MS determination of Synercid injections. J Pharm Biomed Anal. 2003;32:1167–74.PubMedCrossRef
17.
Organization WH. WHO publishes list of bacteria for which new antibiotics are urgently needed. Geneva: WHO; 2017.
18.
Adam HJ, Baxter MR, Davidson RJ, Rubinstein E, Fanella S, Karlowsky JA, Lagacé-Wiens PR, Hoban DJ, Zhanel GG, Alliance CAR. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. J Antimicrob Chemother. 2013;68:i31–7.PubMedCrossRef
19.
Anastasiou DM, Morgan M, Ruane PJ, Steenbergen JN, Katz BD, Alder JD, Thorne GM. In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates. Diagn Microbiol Infect Dis. 2008;61:339–42.PubMedCrossRef
20.
Ayepola OO, Egwari L, Olasehinde GI. Antibiotic resistance profile of Staphylococcus aureus clinical isolates from Nigeria. Antimicrob Resist Infect Control. 2015;4:P195.PubMedCentralCrossRef
21.
Ballow CH, Jones RN, Biedenbach DJ, Group NAZR. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis. 2002;43:75–83.PubMedCrossRef
22.
Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY program report (2003-2004). Int J Antimicrob Agents. 2007;30:143–9.PubMedCrossRef
23.
Biswas S, Watwani J, Vadwai V, Shetty A, Kelkar R, Rodrigues C. Comparative in vitro activities of daptomycin, vancomycin, teicoplanin and linezolid against resistant gram-positive bacterial isolates from two large centres in western India. Int J Antimicrob Agents. 2012;40:567–9.PubMedCrossRef
24.
Błażewicz I, Jaśkiewicz M, Piechowicz L, Neubauer D, Nowicki RJ, Kamysz W, Barańska-Rybak W. Activity of antimicrobial peptides and conventional antibiotics against superantigen positive Staphylococcus aureus isolated from patients with atopic dermatitis. Postepy Dermatol Alergol. 2018;35:74–82.PubMedPubMedCentralCrossRef
25.
Bongiorno D, Mongelli G, Stefani S, Campanile F. Burden of rifampicin- and methicillin-resistant Staphylococcus aureus in Italy. Microb Drug Resist. 2018;24:732–8.PubMedCrossRef
26.
Brzychczy-Wloch M, Borszewska-Kornacka M, Gulczynska E, Wojkowska-Mach J, Sulik M, Grzebyk M, Luchter M, Heczko PB, Bulanda M. Prevalence of antibiotic resistance in multi-drug resistant coagulase-negative staphylococci isolated from invasive infection in very low birth weight neonates in two polish NICUs. Ann Clin Microbiol Antimicrob. 2013;12:41.PubMedPubMedCentralCrossRef
27.
Campanile F, Bongiorno D, Perez M, Mongelli G, Sessa L, Benvenuto S, Gona F, Varaldo PE, Stefani S. Epidemiology of Staphylococcus aureus in Italy: first nationwide survey, 2012. J Glob Antimicrob Resist. 2015;3:247–54.PubMedCrossRef
28.
Cassettari M, Morrissey I. In vitro activity of Telavancin against staphylococci circulating in Europe during 2010 and 2011; 2011.
29.
Castanheira M, Jones RN, Sader HS. Update of the in vitro activity of daptomycin tested against 6710 gram-positive cocci isolated in North America (2006). Diagn Microbiol Infect Dis. 2008;61:235–9.PubMedCrossRef
30.
Chen YH, Liu CY, Ko WC, Liao CH, Lu PL, Huang CH, Lu CT, Chuang YC, Tsao SM, Chen YS, et al. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline in vitro surveillance in Taiwan (TIST) study, 2006-2010. Eur J Clin Microbiol Infect Dis. 2014;33:233–9.PubMedCrossRef
31.
Cui L, Wang Y, Li Y, He T, Schwarz S, Ding Y, Shen J, Lv Y. Cfr-mediated linezolid-resistance among methicillin-resistant coagulase-negative staphylococci from infections of humans. PLoS One. 2013;8:e57096.PubMedPubMedCentralCrossRef
32.
Cuny C, Layer F, Werner G, Harmsen D, Daniels-Haardt I, Jurke A, Mellmann A, Witte W, Kock R. State-wide surveillance of antibiotic resistance patterns and spa types of methicillin-resistant Staphylococcus aureus from blood cultures in North Rhine-Westphalia, 2011-2013. Clin Microbiol Infect. 2015;21:750–7.PubMedCrossRef
33.
Decousser JW, Woerther PL, Soussy CJ, Fines-Guyon M, Dowzicky MJ. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016. Antimicrob Resist Infect Control. 2018;7:68.PubMedPubMedCentralCrossRef
34.
Decousser J-W, Pina P, Picot F, Delalande C, Pangon B, Courvalin P, Allouch P. Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J Antimicrob Chemother. 2003;51:1213–22.PubMedCrossRef
35.
Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of Telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:2383–8.PubMedPubMedCentralCrossRef
36.
Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother. 2005;49:5024–32.PubMedPubMedCentralCrossRef
37.
Duncan LR, Smart JI, Flamm RK, Sader HS, Jones RN, Mendes RE. Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014). Diagn Microbiol Infect Dis. 2016;86:300–2.PubMedCrossRef
38.
Farrell DJ, Mendes RE, Ross JE, Jones RN. Linezolid surveillance program results for 2008 (LEADER program for 2008). Diagn Microbiol Infect Dis. 2009;65:392–403.PubMedCrossRef
39.
Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob Agents Chemother. 2011;55:3684–90.PubMedPubMedCentralCrossRef
40.
Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis. 2012;74:54–61.PubMedCrossRef
41.
Flamm RK, Mendes RE, Hogan PA, Ross JE, Farrell DJ, Jones RN. In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. Diagn Microbiol Infect Dis. 2015;81:283–9.PubMedCrossRef
42.
Flamm RK, Mendes RE, Hogan PA, Streit JM, Ross JE, Jones RN. Linezolid surveillance results for the United States (LEADER surveillance program 2014). Antimicrob Agents Chemother. 2016;60:2273–80.PubMedPubMedCentralCrossRef
43.
Francia MV, Clewell DB. Transfer origins in the conjugative Enterococcus faecalis plasmids pAD1 and pAM373: identification of the pAD1 nic site, a specific relaxase and a possible TraG-like protein. Mol Microbiol. 2002;45:375–95.PubMedCrossRef
44.
Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother. 2002;49:467–70.PubMedCrossRef
45.
Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY program (2005-2008). Braz J Infect Dis. 2009;13:90–8.PubMedCrossRef
46.
Gallon O, Guillet-Caruba C, Lamy B, Laurent F, Doucet-Populaire F, Decousser JW. In vitro activity of daptomycin against staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies. Eur J Clin Microbiol Infect Dis. 2009;28:1209–15.PubMedCrossRef
47.
Gandra S, Mojica N, Klein EY, Ashok A, Nerurkar V, Kumari M, Ramesh U, Dey S, Vadwai V, Das BR, Laxminarayan R. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008-2014. Int J Infect Dis. 2016;50:75–82.PubMedPubMedCentralCrossRef
48.
Garza-González E, Dowzicky MJ. Changes in Staphylococcus aureus susceptibility across Latin America between 2004 and 2010. Braz J Infect Dis. 2013;17:13–9.PubMedCrossRef
49.
Haley RW, Hightower AW, Khabbaz RF, Thornsberry C, Martone WJ, Allen JR, Hughes JM. The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals: possible role of the house staff-patient transfer circuit. Ann Intern Med. 1982;97:297–308.PubMedCrossRef
50.
Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Soderquist B. Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect. 2009;15:238–44.PubMedCrossRef
51.
Hodille E, Delouere L, Bouveyron C, Meugnier H, Bes M, Tristan A, Laurent F, Vandenesch F, Lina G, Dumitrescu O. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Med Mal Infect. 2017;47:152–7.PubMedCrossRef
52.
Hsueh P-R, Chen W-H, Teng L-J, Luh K-T. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents. 2005;26:43–9.PubMedPubMedCentralCrossRef
53.
Isnard C, Dhalluin A, Malandain D, Bruey Q, Auzou M, Michon J, Giard JC, Guerin F, Cattoir V. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections. J Glob Antimicrob Resist. 2018;13:221–5.PubMedCrossRef
54.
Jain S, Gaind R, Chugh TD. In vitro activity of vancomycin and daptomycin against clinical isolates of Staphylococcus aureus and enterococci from India. Int J Antimicrob Agents. 2013;42:94–5.PubMedCrossRef
55.
Jain S, SenGupta M, Jindal N, Ghosh S, Ghosh C. Phylogenetic analysis of cfr mediated linezolid resistance in clinical isolates of MRSA isolated from eastern India. Int J Adv Biotechnol Res. 2015;16:450–8.
56.
Jan E, Camou F, Texier-Maugein J, Whinnett Z, Caubet O, Ploux S, Pellegrin JL, Ritter P, Metayer PL, Roudaut R, et al. Microbiologic characteristics and in vitro susceptibility to antimicrobials in a large population of patients with cardiovascular implantable electronic device infection. J Cardiovasc Electrophysiol. 2012;23:375–81.PubMedCrossRef
57.
Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE Jr, Tenover FC. In vitro activities of Daptomycin, linezolid, and Quinupristin-Dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist. 2003;9:389–93.PubMedCrossRef
58.
John MA, Pletch C, Hussain Z. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci. J Antimicrob Chemother. 2002;50:933–8.PubMedCrossRef
59.
Jones RN, Ballow CH, Biedenbach DJ, Hospital ECM, Hospital SM, Hospital FC, Hospital GM, Pettis Memorial V, Center LLM, Center UM. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox® antimicrobial potency study (ZAPS) in the United States. Diagn Microbiol Infect Dis. 2001;40:59–66.PubMedCrossRef
60.
Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis. 2007;59:309–17.PubMedCrossRef
61.
Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K, ZAAPS International Surveillance Program. For linezolid resistance: results from 5591 gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis. 2007;2009(64):191–201.
62.
Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD. Zyvox annual appraisal of potency and Spectrum program: linezolid surveillance program results for 2008. Diagn Microbiol Infect Dis. 2009;65:404–13.PubMedCrossRef
63.
Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER program for 2007). Diagn Microbiol Infect Dis. 2008;62:416–26.PubMedCrossRef
64.
Kao TM, Wang JT, Weng CM, Chen YC, Chang SC. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC. J Microbiol Immunol Infect. 2011;44:346–51.PubMedCrossRef
65.
Karlowsky JA, Walkty AJ, Baxter MR, Arhin FF, Moeck G, Adam HJ, Zhanel GG. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. Diagn Microbiol Infect Dis. 2017;87:349–56.PubMedCrossRef
66.
Khan MM, Faiz A, Ashshi AM. Clinically significant coagulase negative staphylococci and their antibiotic resistance pattern in a tertiary care hospital. J Pak Med Assoc. 2014;64:1171–4.PubMed
67.
Li X, Arias CA, Aitken SL, Galloway Pena J, Panesso D, Chang M, Diaz L, Rios R, Numan Y, Ghaoui S, et al. Clonal emergence of invasive multidrug-resistant Staphylococcus epidermidis Deconvoluted via a combination of whole-genome sequencing and microbiome analyses. Clin Infect Dis. 2018;67:398–406.PubMedPubMedCentralCrossRef
68.
Limoncu MH, Ermertcan S, Cosar G, Tunger O. In vitro effectiveness of quinupristin/dalfopristin against Staphylococcus aureus strains. Int J Antimicrob Agents. 2003;21:493–5.PubMedCrossRef
69.
Luh K-T, Hsueh P-R, Teng L-J, Pan H-J, Chen Y-C, Lu J-J, Wu J-J, Ho S-W. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother. 2000;44:3374–80.PubMedPubMedCentralCrossRef
70.
Martinez-Melendez A, Morfin-Otero R, Villarreal-Trevino L, Camacho-Ortiz A, Gonzalez-Gonzalez G, Llaca-Diaz J, Rodriguez-Noriega E, Garza-Gonzalez E. Molecular epidemiology of coagulase-negative bloodstream isolates: detection of Staphylococcus epidermidis ST2, ST7 and linezolid-resistant ST23. Braz J Infect Dis. 2016;20:419–28.PubMedCrossRef
71.
Mathai D, Biedenbach DJ, Jones RN, Bell JM, Turnidge J, Sader HS. Activity of daptomycin against gram-positive bacterial isolates from Indian medical centres (2006-2007). Int J Antimicrob Agents. 2009;34:497–9.PubMedCrossRef
72.
McDonald LC, Lauderdale T-L, Shiau Y-R, Chen P-C, Lai J-F, Wang H-Y, Ho M. The status of antimicrobial resistance in Taiwan among gram-positive pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) programme, 2000. Int J Antimicrob Agents. 2004;23:362–70.PubMedCrossRef
73.
Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from north American medical centers. Diagn Microbiol Infect Dis. 2008;60:433–6.PubMedCrossRef
74.
Mendes RE, Sader HS, Farrell DJ, Jones RN. Telavancin activity tested against a contemporary collection of gram-positive pathogens from USA hospitals (2007-2009). Diagn Microbiol Infect Dis. 2012;72:113–7.PubMedCrossRef
75.
Mendes RE, Sader HS, Janechek M, Jones RN: Antimicrobial Spectrum of activity of Telavancin and comparator agents tested against methicillin-resistant Staphylococcus aureus recovered from United States and European hospitals over a 3-year sampling period (2007–2009).
76.
Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, MacGowan A, Janes R, Knight D. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2012;68:164–7.PubMedCrossRef
77.
Mutnick AH, Enne V, Jones RN, Linezolid resistance since. SENTRY Antimicrobial Surveillance Program. Ann Pharmacother. 2001;2003(37):769–74.
78.
Pedroso S, Sandes SHC, Filho RAT, Nunes AC, Serufo JC, Farias LM, Carvalho MAR, Bomfim MRQ, Santos SG. Coagulase-negative staphylococci isolated from human bloodstream infections showed multidrug resistance profile. Microb Drug Resist. 2018;24:635–47.PubMedCrossRef
79.
Petrelli D, Repetto A, D'ercole S, Rombini S, Ripa S, Prenna M, Vitali LA. Analysis of meticillin-susceptible and meticillin-resistant biofilm-forming Staphylococcus aureus from catheter infections isolated in a large Italian hospital. J Med Microbiol. 2008;57:364–72.PubMedCrossRef
80.
Pfaller MA, Mendes RE, Sader HS, Jones RN. Telavancin activity against gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother. 2010;65:2396–404.PubMedCrossRef
81.
Pfaller MA, Mendes RE, Streit JM, Hogan PA, Flamm RK. Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015). Antimicrob Agents Chemother. 2017:61.
82.
Picazo JJ, Betriu C, Culebras E, Rodríguez-Avial I, Gómez M, López F, Group VS. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers. Diagn Microbiol Infect Dis. 2009;64:448–51.PubMedCrossRef
83.
Picazo JJ, Betriu C, Rodriguez-Avial I, Culebras E, Lopez F, Gomez M. Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci. Enferm Infecc Microbiol Clin. 2010;28:13–6.PubMedCrossRef
84.
Picazo JJ, Betriu C, Rodriguez-Avial I, Culebras E, Lopez-Fabal F, Gomez M. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance. Diagn Microbiol Infect Dis. 2011;70:373–9.PubMedCrossRef
85.
Picazo JJ, Betriu C, Rodríguez-Avial I, Culebras E, López-Fabal F, Gómez M, Group VS. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance. Diagn Microbiol Infect Dis. 2011;70:373–9.PubMedCrossRef
86.
Putnam SD, Sader HS, Farrell DJ, Jones RN. Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States medical centers from 2004 through 2008. J Chemother. 2010;22:13–6.PubMedCrossRef
87.
Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS, Biek D, Critchley IA, Diekema DJ, Doern GV. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother. 2011;55:4154–60.PubMedPubMedCentralCrossRef
88.
Rolston KV, Kapadia M, Tarrand J, Coyle E, Prince RA. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients. Int J Antimicrob Agents. 2013;41:516–20..PubMedCrossRef
89.
Rosenthal ME, Mediavilla J, Chen L, Sonnenfeld J, Pierce L, Shannon A, Boucher H, Pearlmutter M, Kreiswirth B, Kuo YH, et al. Molecular epidemiology of Staphylococcus aureus in post-earthquake northern Haiti. Int J Infect Dis. 2014;29:146–51.PubMedCrossRef
90.
Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox annual appraisal of potency and Spectrum program. Diagn Microbiol Infect Dis. 2005;52:53–8.PubMedCrossRef
91.
Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis. 2007;58:363–5.PubMedCrossRef
92.
Sader H. Five-year trend of antimicrobial susceptibility rates and daptomycin activity among Staphylococcus aureus isolates collected in Latin American medical eenters (2005-2009). Int J Infect Dis. 2010;14:e191–2.
93.
Sader HS, Farrell DJ, Flamm RK, Jones RN. Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother. 2014;58:2274–80.PubMedPubMedCentralCrossRef
94.
Sader HS, Farrell DJ, Flamm RK, Jones RN. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). J Antimicrob Chemother. 2015;70:2053–6.PubMed
95.
Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob Agents Chemother. 2013;57:3178–81.PubMedPubMedCentralCrossRef
96.
Sader HS, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Antimicrobial activities of Ceftaroline and comparator agents against bacterial organisms causing bacteremia in patients with skin and skin structure infections in U.S. medical centers, 2008 to 2014. Antimicrob Agents Chemother. 2016;60:2558–63.PubMedPubMedCentralCrossRef
97.
Sader HS, Fritsche TR, Jones RN. Frequency of occurrence and daptomycin susceptibility rates of gram-positive organisms causing bloodstream infections in cancer patients. J Chemother. 2008;20:570–6.PubMedCrossRef
98.
Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients. Int J Infect Dis. 2009;13:291–5.PubMedCrossRef
99.
Sader HS, Fritsche TR, Streit JM, Jones RN. Daptomycin in vitro activity tested against gram-positive strains collected from European and Latin American medical centers in 2003. J Chemother. 2005;17:477–83.PubMedCrossRef
100.
Sader HS, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the Daptomycin surveillance program (2007-2008). Diagn Microbiol Infect Dis. 2009;65:158–62.PubMedCrossRef
101.
Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis. 2005;52:181–6.PubMedCrossRef
102.
Sader HS, Moet GJ, Farrell DJ, Jones RN. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagn Microbiol Infect Dis. 2011;70:412–6.PubMedCrossRef
103.
Sader HS, Streit J, Fritsche T, Jones R. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin surveillance Programme (2002–2004). Clin Microbiol Infect. 2006;12:844–52.PubMedCrossRef
104.
Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis. 2007(7):29.
105.
Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, Bartizal KF. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis. 2015;81:112–8.PubMedCrossRef
106.
Song Y, Lv Y, Cui L, Li Y, Ke Q, Zhao Y. cfr-mediated linezolid-resistant clinical isolates of methicillin-resistant coagulase-negative staphylococci from China. J Glob Antimicrob Resist. 2017;8:1–5.PubMedCrossRef
107.
Stuart JI, John MA, Milburn S, Diagre D, Wilson B, Hussain Z. Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin. Int J Antimicrob Agents. 2011;37:248–52..PubMedCrossRef
108.
Tekin A, Dal T, Deveci O, Tekin R, Ozcan N, Atmaca S, Dayan S. In vitro susceptibility to methicillin, vancomycin and linezolid of staphylococci isolated from bloodstream infections in eastern Turkey. Braz J Microbiol. 2014;45:829–33.PubMedPubMedCentralCrossRef
109.
Vamsimohan A, Gupta S, Muralidharan S. Daptomycin resistance in methicillin-resistant Staphylococcus aureus: a report from southern India. Germs. 2014;4:70–2.PubMedPubMedCentralCrossRef
110.
Vega S, Dowzicky MJ. Antimicrobial susceptibility among gram-positive and gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline evaluation and surveillance trial. Ann Clin Microbiol Antimicrob. 2017;16:50.PubMedPubMedCentralCrossRef
111.
Wang W-Y, Chiueh T-S, Lee Y-T, Tsao S-M. Correlation of molecular types with antimicrobial susceptibility profiles among 670 mecA-positive MRSA isolates from sterile sites (TIST Study, 2006–2010). J Microbiol Immunol Infect. 2015;48:S39.CrossRef
112.
Xi C, Liao W-M, Gong F-Y, Min X, Xiong W, Lai X-Q. Pathogen infection distribution and drug resistance analysis of patients with severe liver disease. Med J Chin Peoples Liberation Army. 2018;43:28–32.
113.
Yousefi M, Fallah F, Arshadi M, Pourmand MR, Hashemi A, Pourmand G. Identification of tigecycline- and vancomycin-resistant Staphylococcus aureus strains among patients with urinary tract infection in Iran. New Microbes New Infect. 2017;19:8–12.PubMedPubMedCentralCrossRef
114.
Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study. J Antimicrob Chemother. 2013;68:i7–i22.PubMedCrossRef
115.
Zhanel GG, Adam HJ, Low DE, Blondeau J, DeCorby M, Karlowsky JA, Weshnoweski B, Vashisht R, Wierzbowski A, Hoban DJ. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis. 2011;69:291–306.PubMedCrossRef
116.
Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagace-Wiens P, Walkty A, Mulvey MR, Hoban DJ. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis. 2008;62:67–80.PubMedCrossRef
117.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
118.
119.
120.
121.
Xiao G, Chen Z, Lv X. Chlorhexidine-based body washing for colonization and infection of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: an updated meta-analysis. Infect Drug Resist. 2018;11:1473–81.PubMedPubMedCentralCrossRef
122.
Darban-Sarokhalil D, Khoramrooz SS, Marashifard M, Hosseini SAAM, Parhizgari N, Yazdanpanah M, Gharibpour F, Mirzaii M, Sharifi B, Haeili M. Molecular characterization of Staphylococcus aureus isolates from southwest of Iran using spa and SCCmec typing methods. Microb Pathog. 2016;98:88–92.PubMedCrossRef
123.
Khan TM, Kok YL, Bukhsh A, Lee LH, Chan KG, Goh BH. Incidence of methicillin resistant Staphylococcus aureus (MRSA) in burn intensive care unit: a systematic review. Germs. 2018;8:113–25.PubMedPubMedCentralCrossRef
124.
Xu Z, Shah HN, Misra R, Chen J, Zhang W, Liu Y, Cutler RR, Mkrtchyan HV. The prevalence, antibiotic resistance and mecA characterization of coagulase negative staphylococci recovered from non-healthcare settings in London, UK. Antimicrob Resist Infect Control. 2018;7:73.PubMedPubMedCentralCrossRef
125.
Zong Z, Peng C, Lü X. Diversity of SCCmec elements in methicillin-resistant coagulase-negative staphylococci clinical isolates. PLoS One. 2011;6:e20191.PubMedPubMedCentralCrossRef
126.
Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55:1162–72.PubMedCrossRef
127.
Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58:1221–9.PubMedCrossRef
128.
Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother. 2005;55:283–8.PubMedCrossRef
129.
Drees M, Boucher H. New agents for Staphylococcus aureus endocarditis. Curr Opin Infect Dis. 2006;19:544–50.PubMedCrossRef
130.
Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007;45:601–8.PubMedCrossRef
131.
Davis SL, McKinnon PS, Hall LM, Delgado G Jr, Rose W, Wilson RF, Rybak MJ. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy. 2007;27:1611–8.PubMedCrossRef
132.
133.
Sakoulas G, Eliopoulos GM, Fowler VG, Moellering RC, Novick RP, Lucindo N, Yeaman MR, Bayer AS. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother. 2005;49:2687–92.PubMedPubMedCentralCrossRef
134.
Gostelow M, Gonzalez D, Smith PB, Cohen-Wolkowiez M. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol. 2014;7:327–40.PubMedPubMedCentralCrossRef
135.
Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2007;45:S184–90.PubMedCrossRef
136.
Zhang S, Sun X, Chang W, Dai Y, Ma X. Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. PLoS One. 2015;10.
Metadata
Title
The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase–negative staphylococci strains: a systematic review and meta-analysis
Authors
Aref Shariati
Masoud Dadashi
Zahra Chegini
Alex van Belkum
Mehdi Mirzaii
Seyed Sajjad Khoramrooz
Davood Darban-Sarokhalil
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2020
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-020-00714-9

Other articles of this Issue 1/2020

Antimicrobial Resistance & Infection Control 1/2020 Go to the issue

Research

Risk factors for fecal carriage of drug-resistant Escherichia coli: a systematic review and meta-analysis

Research

Spread of multidrug resistance among Ureaplasma serovars, Tunisia

Research

The prevalence and mechanism of triclosan resistance in Escherichia coli isolated from urine samples in Wenzhou, China

Research

Effects of restrictive-prescribing stewardship on antibiotic consumption in primary care in China: an interrupted time series analysis, 2012–2017

Research

Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future

Research

Impact of an e-learning module on personal protective equipment knowledge in student paramedics: a randomized controlled trial
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits